Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Oncol Pharm Pract ; 11(2): 63-7, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16460607

ABSTRACT

PURPOSE: Toxicity may distress patients and cause delay or a discontinuance of scheduled chemotherapies. A key issue is to create a reporting system in order to assess toxicities and also evaluate treatments. METHODS: In the Oncology Unit 3,000 intravenous chemotherapies are administered each year, mostly in the day hospital. In summer 2002, oncologists and pharmacists agreed to assess myelosuppression and gastrointestinal toxicity of grades 3 and 4. Pharmacists designed a form and a database in order to collect toxicity data for every patient. The oncologist records type and grade of toxicity (according to the NCI CTC) on the patient chart before chemotherapy commences. During the validation of computerized prescriptions the pharmacist collects data about possible toxicities of every grade. RESULTS: From August-October 2002, 675 chemotherapies were administered. Seventy-two patients developed GI toxicity at various grades, nine of grade 3 and two of grade 4. Regimens with fluorouracil, carboplatin, cisplatin and oxaliplatin were highly involved in GI toxicity. Eighty-seven patients developed myelosuppression, two of grade 3 and 33 of grade 4. Regimens with epirubicin, cyclophosphamide, paclitaxel, cisplatin and carboplatin were highly involved in myelosuppression. After the first report, oncologists and pharmacists decided to stop collecting data in order to improve the reporting system and to plan regular meetings. CONCLUSIONS: A reliable reporting system is a valuable tool for oncologists to manage toxicity and to evaluate chemotherapy regimens. Assessing chemotherapy toxicity is a good opportunity for pharmacists to take part in preventing toxicity and reducing patient's discomfort.


Subject(s)
Antineoplastic Agents/adverse effects , Gastrointestinal Diseases/chemically induced , Hematologic Diseases/chemically induced , Adverse Drug Reaction Reporting Systems/standards , Adverse Drug Reaction Reporting Systems/statistics & numerical data , Drug Prescriptions/standards , Drug Prescriptions/statistics & numerical data , Humans , Injections, Intravenous , Medical Oncology/statistics & numerical data , Medical Records Systems, Computerized/standards , Medical Records Systems, Computerized/statistics & numerical data , Oncology Service, Hospital/standards , Oncology Service, Hospital/statistics & numerical data , Pharmacy Service, Hospital/standards , Pharmacy Service, Hospital/statistics & numerical data , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...